Pay in 4 interest-free payments of $5.94 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
In the GGIT, both the increase in ISR AUC over the 512 mmol/l glucose interval (AUC 512mmol ) from baseline to end of treatment and the increase in the corresponding slope of the ISR vs glucose curve (doseresponse relationship) were significantly greater in the semaglutide group than in the placebo group (ETR [95% CI]: 2.45 [2.16, 2.77] and 2.78 [2.44, 3.16], respectively
doi: 10.1186/s12985-016-0663-7 75 Van ButselaarT.Van den AckervekenG
If your blood sugar goes too low, you will die
A landmark trial of more than 17,600 overweight and obese patients with cardiovascular disease (but not diabetes), found that semaglutide reduced their risk of serious cardiovascular events by 20%
US$ 28.85
US$ 20.41
US$ 27.99
